AstraZeneca on Sunday released results from the first late-stage trial of a fully owned ADC, showing it reduced the risk of death by 42% in patients with advanced gastric cancer who had been ...
Results from the SANOVO Phase III trial evaluating ORPATHYS ® plus TAGRISSO ® in treatment-naïve patients in China with EGFRm locally advanced or metastatic NSCLC and MET overexpression will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results